首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1479851

醣質學市場 - 2024 年至 2029 年預測

Glycomics Market - Forecasts from 2024 to 2029

出版日期: 2024年04月03日 | 出版商:

Knowledge Sourcing Intelligence | 英文 130 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

醣質學市場預計將從 2022 年的 1,438,251,000 美元增加到 2029 年的 2,360,017,000 美元，預測期內複合年成長率為 7.33%。

由於幾個關鍵因素，醣質學市場正在經歷顯著的成長和擴張。關鍵驅動力之一是持續開發新的和增強的聚醣分析技術。質譜儀和聚醣微陣列等設備的進步使得對聚醣的分析變得更加靈敏和特異性，從而推動了市場成長。

此外，政府津貼的增加以及製藥和生物技術公司的研究投資在推動市場擴張方面發揮關鍵作用。隨著研究人員對聚醣在健康和疾病中的作用有了更深入的了解，對醣質學工具和技術的需求不斷增加。

另一個重要的促進因素是對個人化醫療的日益重視。聚醣為了解個體差異和疾病感受性提供了寶貴的見解，有助於開發更有針對性的治療方法。

此外，印度醫藥市場預計到 2024 年將達到 650 億美元，到 2030 年將達到 1,300 億美元，這對改進診斷工具的需求做出了巨大貢獻。

印度供應了全球50%以上的各種疫苗需求和美國40%的非專利需求，而癌症、糖尿病和自體免疫疾病等慢性病盛行率的上升是由對先進診斷方法的需求所推動的。強調了這一必要性。

醣質學在滿足這一需求方面前景廣闊，有可能為這些疾病開發新的診斷方法。

慢性病快速增加

癌症、糖尿病和自體免疫疾病等慢性病的增加需要增強診斷能力。醣質學代表了針對這些疾病創新新診斷方法的有前途的途徑。

在全球範圍內，由於久坐的生活方式、人口老化和環境污染等因素，慢性病呈現上升趨勢。這些疾病，包括癌症、糖尿病和自體免疫疾病，給世界各地的醫療系統帶來了巨大的負擔。

非傳染性疾病（NCD）也稱為慢性病，通常病程較長，是由遺傳、生理、環境和行為因素的複雜交互作用所引起。

據世界衛生組織稱，心血管疾病是最致命的非傳染性疾病，每年約導致1790 萬人死亡，其次是癌症（930 萬人）和慢性呼吸道疾病（410 萬人死亡）和糖尿病（200 萬人，其中包括200 萬人）。

聚醣對於許多生物過程至關重要，其結構和功能的變化與許多慢性疾病的發病和進展密切相關。例如，在癌細胞中發現異常糖鏈，並導致腫瘤生長和轉移。同樣，在糖尿病和自體免疫疾病患者中觀察到聚醣譜的偏差。

俄羅斯和烏克蘭之間持續的衝突預計將對醣質學市場產生微妙的影響。戰爭擾亂了全球供應鏈，導致醣質學研究必需的原料和設備短缺且價格飆升。設備和試劑所需的許多關鍵材料可能生產這些地區，導致延誤並影響研究活動。

此外，衝突正在導致全球經濟嚴重不穩定，這可能導致政府和私人組織的研究經費減少。這可能對整體市場成長構成主要障礙。

然而，在這些挑戰中，衝突可能會加強全球對生物準備和創新診斷和治療開發的重視。此外，現有供應鏈的中斷可能導致調查所必需的關鍵材料和設備的生產區域化。

醣質學酶細分市場的成長預測

糖基轉移酶等酶對於醣質學至關重要，因為它們合成糖鏈並分解碳水化合物。聚醣結構由糖基化酶形成，凝集素有助於識別糖鏈。了解這些酵素對於破解聚醣在生物學中的功能（從疾病病因學到細胞訊號傳導）是必要的。他們的研究有助於開發特定糖鏈的診斷藥物和治療方法。

不斷發展的生物醫學行業依賴糖酶進行藥物發現、診斷和治療方法，並且認知到聚醣是重要的生物標記和治療標靶。學術界、工業界和研究機構的共同努力正在推動新型醣質學酶的開發，這些酶專為從工業生物技術到醫學的各種應用而客製化，進一步推動了成長軌跡。

據緬因州政府 DECD 稱，到 2022 年，緬因州的生物醫學製造業將需要 30 億美元的活動，其中 23 億美元（77%）將來自州外。緬因州生物醫學製造業的國外進口額為 1.201 億美元。緬因州 5.1% 的進口需求是透過從州外進口來滿足的，這表明用於生物醫學製造的進口產品 94.9% 是在當地採購的。此外，導航、測量、醫療和控制儀器是 2022 年緬因州最主要的進口產品之一，估計價值 9,000 萬美元。到 2022 年，這將佔州外進口總額的 1.1%。

此外，由於科學研究、技術進步和工業應用擴大等多種因素，聚醣相關酵素的數量正在增加。隨著研究揭示聚醣在生物過程和疾病機制中發揮的複雜功能，對參與聚醣合成、修飾、酶工程和分解的酶的需求不斷增加。

由於潛在蛋白質的搜尋空間廣泛，酶工程通常涉及尋找具有某些所需活性的酶的起點，然後進行受控進化以增加其對特定應用的「適用性」。據 OSTI 稱，機器學習 (ML) 近年來已成為支援這種啟發式方法的強大工具。

總體而言，由於生物醫學應用的增加、研究的成長和技術的改進，酶市場預計將顯著成長。市場參與企業有很多機會創造適合工業生物技術、診斷和藥物開發需求的獨特酵素。這為該領域的創新和資金籌措開闢了可能性，進一步刺激了市場。

鼓勵研究的政府計劃，例如向大學提供研究津貼貸款，刺激創新和團隊合作，並幫助擴大市場。此外，支持醣質學技術在醫學和商業中使用的監管法規也透過營造有利於醣質學酶商業化和接受的氛圍來支持市場成長。

鞘醣脂對於神經系統中的細胞識別和通訊至關重要。近年來，異常糖基化在癌症研究中引起了越來越多的關注，主要集中在兩個方面。 FDA核准的大多數腫瘤標記是糖蛋白或糖類抗原，異常糖基化是一種非侵入性腫瘤生物標記物，糖基化對於癌症的發生、進展和轉移至關重要。

此外，根據歐盟委員會的說法，GlycoHIT 的目標是創建一種用於臨床樣本中蛋白質糖基化分析的高通量 (HTP) 技術，重點是早期、準確和快速檢測癌症。對於探索性研究目的，目前的蛋白質糖基化分析方法，例如質譜 (MS) 和高效液相層析(HPLC) 是合適的。蛋白質糖基化的 HTP 分析需要新的技術平台和現有技術的進一步發展。此外，GlycoHIT 合作將突破目前技術的極限，創造未來技術，從而對從臨床和生物製藥樣本中獲得的蛋白質進行更快速、更多元化的糖基化分析。

除了策略上專注於聯盟和收購以擴大產品系列和市場佔有率外，市場參與企業還投資於研發，以生產具有擴展功能的創新酶。例如，Creative Proteomics 提供 O-聚醣結合分析服務、N-聚醣結合分析服務、糖蛋白質體學服務、O-聚醣分析和 N-聚醣分析等服務。

預計北美地區市場將會成長。

隨著慢性病負擔的增加，開發新藥變得必要。聚醣與多種疾病有關，包括癌症、心臟病和感染疾病，並參與多種生物過程。例如，根據美國癌症協會的數據，美國新患者估計為男性 983,160 例，女性 934,870 例。

此外，了解聚醣概況以及它們如何與蛋白質和細胞相互作用對於確定潛在的治療標靶和設計有效的藥物是必要的。在美國，由於藥物發現和藥物開發過程的整合，藥物篩檢平台、伴同性診斷和改進的基於聚醣的療法也在開發中。

此外，在美國，藥物發現和藥物開發中對聚醣靶向的關注正在增加對研發和技術的需求，提供了顯著的成長前景。例如，透明質酸是一種天然存在的糖胺聚醣Glico單元，在醫學上有多種用途。它應用於手術傷口，在骨關節炎的治療中發揮重要作用。對先進治療的需求不斷增加以及政府對研發的資助增加，支持了當地產業的成長。例如，2023年4月，NIH啟動了Glico計劃，以鼓勵糖科學領域的糖生物學研究。Glico計劃創建了多種工具、資源和訊息，以幫助不熟悉聚醣的研究人員將其納入他們的研究中。這包括識別特別困難的聚醣的方法、用於研究細菌細胞壁中的聚醣的探針、聚醣化學合成的標準、高通量聚醣研究的方法以及與糖科學相關的工具。

許多產品為學術、製藥和研究機構的研究人員的實驗和研究提供了便利。其他公司則專注於將研究成果轉化為有用的商業應用。這些公司為各種市場生產和銷售基於聚醣的產品，包括營養補充、生物製藥和診斷。例如，安捷倫科技公司於 2023 年 6 月推出了 Agilent BioTek 406 FX 清洗分配器。這是一款集板清洗和多用途試劑分配功能於一體的小型設備。 BioTek 406 FX 具有擴展的液體處理功能，既適合獨立桌面使用，也適合整合到自動化系統中。

此外，賽默飛世爾科技於 2022 年 9 月推出了 DynaSpinTM 拋棄式離心機系統。該系統專門為大規模細胞培養物收穫提供理想的一次性選擇。此外，它透過減少完成收穫過程所需的深度過濾濾芯的數量，增強和簡化了一次性生物過程中細胞培養分離的收穫。

主要參與企業

Merck KGaA 是醣質學市場的領先參與企業，為聚醣分析和研究提供廣泛的產品和解決方案。 Merck KGaA 專注於創新和技術，為研究人員提供工具和試劑來推進他們的醣質學研究。
Thermo Fisher Scientific Inc. 是醣質學市場的另一家領先參與企業，以其專注於聚醣分析的全面分析儀器、耗材和軟體解決方案組合而聞名。
Takara Bio Inc.提供高品質的試劑、套件和設備。我們專注於簡化工作流程和提高實驗重現性，提供創新的解決方案來支援聚醣分析並加速該領域的發現。

The glycomics market is experiencing significant growth and expansion, driven by several key factors. One major driver is the continuous development of new and enhanced technologies for glycan analysis. Advancements in instruments such as mass spectrometers and glycan microarrays enable more sensitive and specific analysis of glycans, thus propelling the market growth.

Moreover, increased government funding and investments by pharmaceutical and biotech companies in glycomics research play a crucial role in driving market expansion. As researchers delve deeper into understanding the role of glycans in health and disease, the demand for glycomics tools and techniques continues to rise.

Another important driver is the growing emphasis on personalized medicine. Glycans provide valuable insights into individual variations and disease susceptibility, facilitating the development of more targeted therapies.

Additionally, the Indian pharmaceutical market, currently valued at $65 billion in 2024 and projected to reach $130 billion by 2030, is contributing significantly to the demand for improved diagnostic tools.

With India supplying over 50% of the global demand for various vaccines and 40% of the generic demand in the US, the rising prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders further emphasizes the need for advanced diagnostic methods.

Glycomics, with its potential for developing novel diagnostic approaches for these diseases, holds immense promise in meeting this demand.

Surge in chronic diseases

The increasing prevalence of chronic illnesses such as cancer, diabetes, and autoimmune conditions is driving the demand for enhanced diagnostic capabilities. Glycomics present a promising avenue for innovating new diagnostic methodologies tailored to these ailments.

Globally, chronic diseases are on the ascent, a trend attributable to factors like sedentary lifestyles, aging populations, and environmental pollutants. These conditions, which include cancer, diabetes, and autoimmune disorders, impose substantial burdens on healthcare systems worldwide.

Noncommunicable diseases (NCDs), also referred to as chronic diseases, are typically prolonged in duration and result from a complex interplay of genetic, physiological, environmental, and behavioral elements.

According to WHO, cardiovascular diseases claim the most lives among NCDs, accounting for approximately 17.9 million fatalities annually, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, including deaths related to kidney disease caused by diabetes).

Glycans are integral to numerous biological processes, and alterations in their structure and function are closely linked to the onset and advancement of many chronic ailments. For example, abnormal glycans are identified in cancer cells, contributing to tumor proliferation and metastasis. Similarly, deviations in glycan profiles are observed in individuals with diabetes and autoimmune disorders.

The ongoing conflict between Russia and Ukraine is expected to have a nuanced effect on the Glycomics market. The war has resulted in disruptions to global supply chains, leading to scarcities and price escalations for essential raw materials and equipment utilized in glycomics research. Many critical materials required for instruments and reagents may originate from these regions, causing delays and impacting research endeavors.

Furthermore, the conflict has induced substantial economic instability worldwide, potentially resulting in reduced research funding from both governmental sources and private entities. This could pose a significant obstacle to overall market growth.

However, amidst these challenges, the conflict may intensify the global emphasis on biopreparedness and the development of innovative diagnostics and therapeutics. Additionally, the disruption of existing supply chains may prompt a shift towards regionalization of production for key materials and equipment essential to glycomics research.

The glycomics enzymes segment is estimated to grow

Enzymes such as glycosyltransferases are essential to glycomics because they synthesize glycoconjugates and degrade carbohydrates. Glycan structures are shaped by glycan-modifying enzymes, and lectins help recognize glycans. Deciphering the functions of glycans in biology, ranging from causes of disease to cell signaling, requires an understanding of these enzymes. Their research aids in the creation of diagnostics and treatments based on glycans.

The growing biomedical industry is dependent on glycomic enzymes for drug discovery, diagnosis, and treatment approaches, driven by the understanding that glycans are important biomarkers and targets for therapeutics. The development of novel glycomics enzymes is customized to a range of applications, from industrial biotechnology to healthcare, and is driven by joint efforts among academia, industry, and research organizations, which further fuel the growth trajectory.

In 2022, as per the DECD (Government of Maine), the biomedical manufacturing sector in Maine required $3.0 billion in activity; of that amount, $2.3 billion, or 77%, came from outside the state. Maine's biomedical manufacturing industry imports are worth $120.1 million from overseas. 5.1% of Maine's import demand is satisfied by imports from outside the state, suggesting that local sources account for 94.9% of all imports of goods used in biomedical manufacturing. Furthermore, instruments for navigation, measurement, medicine, and control rank as the top imports into Maine in 2022, with an estimated value of $90 million. In 2022, this represents 1.1% of total imports from outside the state.

Furthermore, glycomic enzymes are increasing due to various factors, including scientific study, technical advancements, and growing industrial applications. The need for enzymes involved in glycan synthesis, modification, enzyme engineering, and degradation is growing as research reveals the complex functions that glycans play in biological processes and disease mechanisms.

Enzyme engineering often entails finding an enzyme starting point that has some degree of the desired activity, followed by controlled evolution to increase its "fitness" for a specific application, due to the large search space of potential proteins. As per the OSTI, Machine learning (ML) has become a potent tool to support this empirical approach in recent times.

Comprehensively, the glycomics enzymes market is expected to increase significantly due to rising biomedical applications, growing research, and technological improvements. Market participants have many opportunities to create unique enzymes that are suited to the needs of industrial biotechnology, diagnostics, and medication development. This opens the door for more innovation and funding in this field, further fueling the market.

Government programs that encourage glycomics research, such as grants for research and financing for universities, are stimulating innovation and teamwork, which is propelling the market's expansion. Furthermore, regulatory regulations that support the use of glycomics technologies in healthcare and business also aid in market growth by fostering an atmosphere that is favorable for the commercialization and acceptance of glycomics enzymes.

Glycosphingolipids are crucial for cell identification and communication in the nervous system. Abnormal glycosylation has drawn increasing attention in cancer research in the past few years, primarily in two areas. The majority of FDA-approved tumour markers are glycoprotein or glycan antigens, and aberrant glycosylation is a non-invasive tumour biomarker, glycosylation is crucial to the onset, progression, and metastasis of cancer.

Furthermore, as per the European Commission, the goal of GlycoHIT has been to create high throughput (HTP) technologies for the analysis of protein glycosylation in clinical samples, with a focus on early, precise, and fast cancer detection. For the goal of discovery research, current methods for analysing protein glycosylation, such as mass spectrometry (MS) and high-performance liquid chromatography (HPLC), are appropriate. To undertake HTP analysis of protein glycosylation, new technical platforms and additional advancements in already-existing technologies are required. In addition, to create future technologies that allow for quicker and multiplexed analysis of glycosylation on proteins from clinical and biopharmaceutical samples, the GlycoHIT collaboration pushes the boundaries of current technology.

In addition to strategically concentrating on alliances and acquisitions to broaden their product portfolios and market presence, industry participants are investing in research and development to produce innovative glycomics enzymes with expanded functionality. For instance, Creative Proteomics offers services such as O-Glycan linkage analysis service, N-glycan linkage analysis service, glycoproteomics service, O-glycan profiling, and N-glycan profiling, among others.

The market is projected to grow in the North American region.

New drug development is becoming necessary as the burden of chronic diseases rises. Glycans have been connected to a wide range of illnesses, such as cancer, heart problems, and infectious diseases, and are involved in several biological processes. For instance, the estimated number of new cases of cancer in the United States was 9,83,160 among males and 9,34,870 among females as per the American Cancer Society.

Moreover, determining possible therapeutic targets and creating efficient medication designs require an understanding of the glycan profiles and how they interact with proteins and cells. Improved drug screening platforms, companion diagnostics, and glycan-based therapies have also been developed as a result of integration with drug discovery and development processes in the United States.

Further, the demand for research and technologies in the United States has been driven by the focus on targeting glycans in drug discovery and development, making this a major growth prospect. For instance, hyaluronan, a naturally occurring glycosaminoglycan disaccharide unit, has numerous uses in medicine. It is applied to surgical wounds and plays a crucial role in the management of osteoarthritis . Regional industry growth is being aided by the rising demand for advanced therapeutics and the government's increased financing of research and development. For instance, the NIH launched the Glycoscience program to encourage glycobiology research in glycan science, in April 2023 . The Glycoscience program has created several tools, resources, and information to help researchers unfamiliar with glycans incorporate them into their studies. This covers methods for recognizing particularly challenging glycans, probes to investigate glycans in bacterial cell walls, standards for glycan chemical synthesis, approaches for high-throughput glycan investigations, and instructional materials related to glycoscience.

Many products have facilitated the execution of glycomics experiments and investigations by academic, pharmaceutical, and research institute researchers. Some businesses also concentrate on converting research into useful commercial applications. They create and sell glycan-based goods for a range of markets, including nutraceuticals, biopharmaceuticals, and diagnostics. For instance, Agilent Technologies Inc. introduced the Agilent BioTek 406 FX washer dispenser in June 2023. It is a small device that combines plate-washing and multipurpose reagent dispensing capabilities. With its extended liquid handling features, the BioTek 406 FX is intended for both standalone benchtop use and integration into automated systems.

Additionally, Thermo Fisher Scientific Inc. introduced the DynaSpinTM Single-Use Centrifuge system in September 2022. The system is specifically made to offer the best single-use option for harvesting cell cultures on a large scale. Moreover, by lowering the quantity of depth filtration cartridges needed to finish the harvest process, it enhances and simplifies harvesting for cell culture separation in single-use bioprocesses.

Key Players:

Merck KGaA is a leading player in the glycomics market, offering a range of products and solutions for glycan analysis and research. With a strong emphasis on innovation and technology, Merck KGaA provides researchers with tools and reagents to advance glycomics research.
Thermo Fisher Scientific Inc. is another prominent player in the glycomics market, known for its comprehensive portfolio of analytical instruments, consumables, and software solutions tailored for glycan analysis. Its cutting-edge technologies enable precise characterization and quantification of complex glycomes.
Takara Bio Inc. specializes in providing high-quality reagents, kits, and instruments for glycomics research. Focusing on simplifying workflows and enhancing experimental reproducibility, it offers innovative solutions to support glycan analysis and accelerate discoveries in the field.

Segmentation:

By Product

Enzymes
Instruments
Kits
Others

By Application

Drug Discovery
Diagnostics
Others

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
UK
Germany
France
Italy
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
India
South Korea
Taiwan
Thailand
Indonesia
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the Stakeholders

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings
3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View

5. GLYCOMICS MARKET BY PRODUCT

5.1. Introduction
5.2. Enzymes
- 5.2.1. Market Trends and Opportunities
- 5.2.2. Growth Prospects
- 5.2.3. Geographic Lucrativeness
5.3. Instruments
- 5.3.1. Market Trends and Opportunities
- 5.3.2. Growth Prospects
- 5.3.3. Geographic Lucrativeness
5.4. Kits
- 5.4.1. Market Trends and Opportunities
- 5.4.2. Growth Prospects
- 5.4.3. Geographic Lucrativeness
5.5. Others
- 5.5.1. Market Trends and Opportunities
- 5.5.2. Growth Prospects
- 5.5.3. Geographic Lucrativeness

6. GLYCOMICS MARKET BY APPLICATION

6.1. Introduction
6.2. Drug Discovery
- 6.2.1. Market Trends and Opportunities
- 6.2.2. Growth Prospects
- 6.2.3. Geographic Lucrativeness
6.3. Diagnostics
- 6.3.1. Market Trends and Opportunities
- 6.3.2. Growth Prospects
- 6.3.3. Geographic Lucrativeness
6.4. Others
- 6.4.1. Market Trends and Opportunities
- 6.4.2. Growth Prospects
- 6.4.3. Geographic Lucrativeness

7. GLYCOMICS MARKET BY GEOGRAPHY

7.1. Introduction
7.2. North America
- 7.2.1. By Product
- 7.2.2. By Application
- 7.2.3. By Country
  - 7.2.3.1. United States
    - 7.2.3.1.1. Market Trends and Opportunities
    - 7.2.3.1.2. Growth Prospects
  - 7.2.3.2. Canada
    - 7.2.3.2.1. Market Trends and Opportunities
    - 7.2.3.2.2. Growth Prospects
  - 7.2.3.3. Mexico
    - 7.2.3.3.1. Market Trends and Opportunities
    - 7.2.3.3.2. Growth Prospects
7.3. South America
- 7.3.1. By Product
- 7.3.2. By Application
- 7.3.3. By Country
  - 7.3.3.1. Brazil
    - 7.3.3.1.1. Market Trends and Opportunities
    - 7.3.3.1.2. Growth Prospects
  - 7.3.3.2. Argentina
    - 7.3.3.2.1. Market Trends and Opportunities
    - 7.3.3.2.2. Growth Prospects
  - 7.3.3.3. Others
    - 7.3.3.3.1. Market Trends and Opportunities
    - 7.3.3.3.2. Growth Prospects
7.4. Europe
- 7.4.1. By Product
- 7.4.2. By Application
- 7.4.3. By Country
  - 7.4.3.1. Germany
    - 7.4.3.1.1. Market Trends and Opportunities
    - 7.4.3.1.2. Growth Prospects
  - 7.4.3.2. France
    - 7.4.3.2.1. Market Trends and Opportunities
    - 7.4.3.2.2. Growth Prospects
  - 7.4.3.3. UK
    - 7.4.3.3.1. Market Trends and Opportunities
    - 7.4.3.3.2. Growth Prospects
  - 7.4.3.4. Others
    - 7.4.3.4.1. Market Trends and Opportunities
    - 7.4.3.4.2. Growth Prospects
7.5. Middle East and Africa
- 7.5.1. By Product
- 7.5.2. By Application
- 7.5.3. By Country
  - 7.5.3.1. Saudi Arabia
    - 7.5.3.1.1. Market Trends and Opportunities
    - 7.5.3.1.2. Growth Prospects
  - 7.5.3.2. UAE
    - 7.5.3.2.1. Market Trends and Opportunities
    - 7.5.3.2.2. Growth Prospects
  - 7.5.3.3. Others
    - 7.5.3.3.1. Market Trends and Opportunities
    - 7.5.3.3.2. Growth Prospects
7.6. Asia Pacific
- 7.6.1. By Product
- 7.6.2. By Application
- 7.6.3. By Country
  - 7.6.3.1. China
    - 7.6.3.1.1. Market Trends and Opportunities
    - 7.6.3.1.2. Growth Prospects
  - 7.6.3.2. India
    - 7.6.3.2.1. Market Trends and Opportunities
    - 7.6.3.2.2. Growth Prospects
  - 7.6.3.3. Japan
    - 7.6.3.3.1. Market Trends and Opportunities
    - 7.6.3.3.2. Growth Prospects
  - 7.6.3.4. South Korea
    - 7.6.3.4.1. Market Trends and Opportunities
    - 7.6.3.4.2. Growth Prospects
  - 7.6.3.5. Taiwan
    - 7.6.3.5.1. Market Trends and Opportunities
    - 7.6.3.5.2. Growth Prospects
  - 7.6.3.6. Thailand
    - 7.6.3.6.1. Market Trends and Opportunities
    - 7.6.3.6.2. Growth Prospects
  - 7.6.3.7. Indonesia
    - 7.6.3.7.1. Market Trends and Opportunities
    - 7.6.3.7.2. Growth Prospects
  - 7.6.3.8. Others
    - 7.6.3.8.1. Market Trends and Opportunities
    - 7.6.3.8.2. Growth Prospects